In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 196 for your search:

Cancer Type/Condition:  Leukemia, chronic lymphocytic (CLL)
Stage/Subtype:  refractory chronic lymphocytic leukemia
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: NCI
Protocol IDs: CBMTG-0601, NCT00438958

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-CLL-002, NCT00774345

Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Adult
Sponsor: Pharmaceutical / Industry
Protocol IDs: 112517, NCT01039376

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412

A Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GS-US-312-0117, NCT01539291

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GS-US-312-0116, NCT01539512

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GS-US-312-0115, NCT01569295

A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714 AM2)

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P07714, 2011-005186-20, NCT01580228

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR100840, PCI-32765CLL3001, 2012-000600-15, U1111-1135-3745, NCT01611090

10.

A Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GS-US-312-0119, NCT01659021

11.

An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)

Phase: Phase III
Type: Treatment
Status: Active
Age: 65 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-1116-CA, 2012-003968-44, NCT01724346

12.

Stem Cell Transplant for Hematologic Diseases

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: 8713-HIMSUM, NCT00058825

13.

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: CDR0000447204, P30CA016058, OHSU-HEM-05011-L, OHSU-210, NCT00245037

14.

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 05-103, MSKCC-05103, NCT00295932

15.

Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 to 99
Sponsor: NHLBI
Protocol IDs: 060228, 06-H-0228, NHLBI-06-H-0228, NCT00366418

16.

Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 06-138, MSKCC-06138, NCT00466531

17.

Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 69
Sponsor: NCI
Protocol IDs: 070195, 07-C-0195, NCI-07-C-0195, NCT00520130

18.

Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144

19.

Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Relapsed B-Cell Non-Hodgkin Lymphoma

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 85
Sponsor: NCI, Other
Protocol IDs: CDR0000615128, P30CA069533, OHSU-4180, HEM-08002-L, MERCK-OHSU-4180, 4180, OHSU-HEM-08002-L, NCT00764517

20.

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, FHCRC-2230.00, IR-6771, NCT00789776

21.

A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCLL084993, NCT00829647

22.

Phase I/II Study of B Cell Malignancies Using T Cells Expressing an Anti-CD19 Chimeric Receptor: Assessment of the Impact of Lymphocyte Depletion Prior to T Cell Transfer

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 090082, 09-C-0082, NCT00924326

23.

Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MC088C, NCI-2009-00935, 08-008775, NCT00935792

24.

Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-0132, NCT00943319

25.

Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-421, NCT01066663

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map